Gene · 8764
Papers3,537
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1,141 to 1,160 of 3,537
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Immune Subtypes in LUAD Identify Novel Tumor Microenvironment Profiles With Prognostic and Therapeutic Implications. | Front Immunol | 2022 | 35720373 | PubTator, text mining | PubMed |
| Single-Cell RNA and ATAC Sequencing Reveal Hemodialysis-Related Immune Dysregulation of Circulating Immune Cell Subpopulations. | Front Immunol | 2022 | 35720370 | PubTator, text mining | PubMed |
| Immune Microenvironment in Osteosarcoma: Components, Therapeutic Strategies and Clinical Applications. | Front Immunol | 2022 | 35720360 | PubTator, text mining | PubMed |
| The Correlation Between Immune Invasion and SARS-COV-2 Entry Protein ADAM17 in Cancer Patients by Bioinformatic Analysis. | Front Immunol | 2022 | 35720350 | PubTator, text mining | PubMed |
| A Novel Secreted Protein-Related Gene Signature Predicts Overall Survival and Is Associated With Tumor Immunity in Patients With Lung Adenocarcinoma. | Front Oncol | 2022 | 35719915 | PubTator, text mining | PubMed |
| Inflammation-Related LncRNAs Signature for Prognosis and Immune Response Evaluation in Uterine Corpus Endometrial Carcinoma. | Front Oncol | 2022 | 35719911 | PubTator, text mining | PubMed |
| An armed oncolytic virus enhances the efficacy of tumor-infiltrating lymphocyte therapy by converting tumors to artificial antigen-presenting cells in situ. | Mol Ther | 2022 | 35715953 | PubTator, text mining | PubMed |
| The Pyroptosis-Related Long Noncoding RNA Signature Predicts Prognosis and Indicates Immunotherapeutic Efficiency in Hepatocellular Carcinoma. | Front Cell Dev Biol | 2022 | 35712653 | PubTator, text mining | PubMed |
| The Value of m5C-Related lncRNAs in the Prognostic Assessment and Immunotherapy of Stomach Adenocarcinoma. | Biomed Res Int | 2022 | 35711526 | PubTator, text mining | PubMed |
| Comparative study on the mutation spectrum of tissue DNA and blood ctDNA in patients with non-small cell lung cancer. | Transl Cancer Res | 2022 | 35706796 | PubTator, text mining | PubMed |
| Characterization of multiple soluble immune checkpoints in individuals with different Mycobacterium tuberculosis infection status and dynamic changes during anti-tuberculosis treatment. | BMC Infect Dis | 2022 | 35701741 | PubTator, text mining | PubMed |
| Adaptive stress response genes associated with breast cancer subtypes and survival outcomes reveal race-related differences. | NPJ Breast Cancer | 2022 | 35697736 | PubTator, text mining | PubMed |
Comprehensive Molecular Analyses of a Macrophage-Related Gene Signature With Regard to Prognosis, Immune Features, and Biomarkers for Immunotherapy in Hepatocellular Carcinoma Based on WGCNA and the LASSO Algorithm. | Front Immunol | 2022 | 35693827 | PubTator, text mining | PubMed |
| SLC6A8 is a Potential Biomarker for Poor Prognosis in Lung Adenocarcinoma. | Front Genet | 2022 | 35692837 | PubTator, text mining | PubMed |
| MSLN Correlates With Immune Infiltration and Chemoresistance as a Prognostic Biomarker in Ovarian Cancer. | Front Oncol | 2022 | 35692779 | PubTator, text mining | PubMed |
| The immune landscape of solid pediatric tumors. | J Exp Clin Cancer Res | 2022 | 35690832 | PubTator, text mining | PubMed |
| Alpha-smooth muscle actin-positive cancer-associated fibroblasts secreting osteopontin promote growth of luminal breast cancer. | Cell Mol Biol Lett | 2022 | 35690734 | PubTator, text mining | PubMed |
| Genetic characterization and drug sensitivity study of newly derived HGBL double/triple-hit lymphoma cell lines. | Blood Adv | 2022 | 35687491 | PubTator, text mining | PubMed |
| Genomic characterization of lymphomas in patients with inborn errors of immunity. | Blood Adv | 2022 | 35687490 | PubTator, text mining | PubMed |
| Special Issue: Structure, Function and Evolution of Protein Domains. | Int J Mol Sci | 2022 | 35682878 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/8764/papers?page=58